company background image
GLMD

Galmed Pharmaceuticals NasdaqCM:GLMD Stock Report

Last Price

US$0.32

Market Cap

US$8.0m

7D

-16.1%

1Y

-88.8%

Updated

28 Sep, 2022

Data

Company Financials +
GLMD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

GLMD Stock Overview

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.

Galmed Pharmaceuticals Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Galmed Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.32
52 Week HighUS$3.13
52 Week LowUS$0.31
Beta1.34
1 Month Change-30.67%
3 Month Change-50.94%
1 Year Change-88.81%
3 Year Change-91.95%
5 Year Change-96.37%
Change since IPO-97.82%

Recent News & Updates

Aug 04

Galmed GAAP EPS of -$0.15 beats by $0.09

Galmed press release (NASDAQ:GLMD): Q2 GAAP EPS of -$0.15 beats by $0.09. Cash and cash equivalents, restricted cash and marketable debt securities totaled $22.5 million as of June 30, 2022, compared to $34.9 million at December 31, 2021.

May 03
Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

GLMDUS BiotechsUS Market
7D-16.1%2.9%-2.0%
1Y-88.8%-24.2%-20.3%

Return vs Industry: GLMD underperformed the US Biotechs industry which returned -27.4% over the past year.

Return vs Market: GLMD underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is GLMD's price volatile compared to industry and market?
GLMD volatility
GLMD Average Weekly Movement9.5%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: GLMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: GLMD's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200022Allen Baharaffhttps://www.galmedpharma.com

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

Galmed Pharmaceuticals Ltd. Fundamentals Summary

How do Galmed Pharmaceuticals's earnings and revenue compare to its market cap?
GLMD fundamental statistics
Market CapUS$8.00m
Earnings (TTM)-US$25.04m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GLMD income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$25.04m
Earnings-US$25.04m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.00
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GLMD perform over the long term?

See historical performance and comparison